Key Points
- Ra Capital Management, a major shareholder in Werewolf Therapeutics, sold 376,526 shares on May 8 at an average price of $0.71, totaling about $267,333. The sale cut its position by 47.34% to 418,813 shares.
- Ra Capital also sold additional shares on May 11 and May 12, continuing the recent insider selling trend. Those transactions were valued at roughly $58,618 and $64,737, respectively.
- Werewolf Therapeutics shares were trading near $0.63, close to their 52-week low of $0.53. Despite a recent quarterly loss, the company reported earnings that beat estimates, and analysts currently have a Hold consensus with an average price target of $3.75.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock in a transaction on Monday, May 11th. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16. Following the transaction, the director directly owned 1,239,060 shares in the company, valued at approximately $830,170.20. This represents a 2.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
- On Friday, May 8th, Luke Evnin sold 305,741 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.70, for a total transaction of $214,018.70.
- On Thursday, May 7th, Luke Evnin sold 79,086 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $49,824.18.
- On Wednesday, May 6th, Luke Evnin sold 14,635 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.66, for a total transaction of $9,659.10.
- On Tuesday, May 5th, Luke Evnin sold 6,860 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $4,733.40.
- On Monday, May 4th, Luke Evnin sold 47,963 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $34,533.36.
- On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $42,627.62.
- On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total transaction of $121,148.64.
- On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total transaction of $39,025.71.
- On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total transaction of $69,650.76.
Werewolf Therapeutics Stock Down 4.3%
Shares of NASDAQ HOWL opened at $0.63 on Wednesday. The company's fifty day moving average is $0.81 and its 200-day moving average is $0.83. The stock has a market cap of $30.72 million, a price-to-earnings ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a twelve month low of $0.53 and a twelve month high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.32) by $0.04. On average, research analysts anticipate that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.
Analyst Ratings Changes
A number of brokerages recently commented on HOWL. Wall Street Zen lowered shares of Werewolf Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday. Weiss Ratings restated a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $3.75.
View Our Latest Research Report on HOWL
Institutional Investors Weigh In On Werewolf Therapeutics
A number of hedge funds and other institutional investors have recently made changes to their positions in HOWL. Regal Investment Advisors LLC grew its position in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company's stock valued at $33,000 after purchasing an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. grew its position in Werewolf Therapeutics by 66.7% in the fourth quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company's stock valued at $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the second quarter valued at $48,000. AQR Capital Management LLC bought a new position in shares of Werewolf Therapeutics in the 1st quarter valued at about $79,000. Finally, Bridgeway Capital Management LLC grew its holdings in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company's stock valued at $111,000 after acquiring an additional 62,414 shares in the last quarter. 64.84% of the stock is currently owned by institutional investors and hedge funds.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
